P005 ANALYSIS OF PREDICTORS OF RESPONSE MAINTENANCE TO CERTOLIZUMAB PEGOL IN PATIENTS WITH ACTIVE CROHN'S DISEASE: DATA FROM PRECISE 2

S. Hanauer(University of Illinois Chicago), W. Sandborn, Gary R. Lichtenstein(University of Pennsylvania), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Ole Østergaard Thomsen(University of Copenhagen), Ralph Bloomfield(AstraZeneca (United Kingdom))
Journal of Crohn s and Colitis Supplements
February 1, 2008
10.1016/s1873-9954(08)70016-8
Cited by 2

Related Papers

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Transcriptome and genome sequencing uncovers functional variation in humans
|Nature|2013|2.2k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k